

UNCLASSIFIED

Exhibit R-2, RDT&E Budget Item Justification: PB 2013 Navy	DATE: February 2012
---	----------------------------

APPROPRIATION/BUDGET ACTIVITY 1319: <i>Research, Development, Test & Evaluation, Navy</i> BA 5: <i>Development & Demonstration (SDD)</i>	R-1 ITEM NOMENCLATURE PE 0604771N: <i>Medical Development</i>
---	---

COST (\$ in Millions)	FY 2011	FY 2012	FY 2013 Base	FY 2013 OCO	FY 2013 Total	FY 2014	FY 2015	FY 2016	FY 2017	Cost To Complete	Total Cost
Total Program Element	28.407	33.034	12.707	2.173	14.880	9.471	9.665	10.253	10.450	Continuing	Continuing
0933: <i>Medical/Dental Equipment Dev</i>	11.693	14.934	12.707	2.173	14.880	9.471	9.665	10.253	10.450	Continuing	Continuing
9999: <i>Congressional Adds</i>	16.714	18.100	-	-	-	-	-	-	-	0.000	34.814

A. Mission Description and Budget Item Justification

The purpose of this budget item is to develop biomedical equipment and related techniques to reduce morbidity; to enhance the logistic feasibility of modern medical care for combat casualties; to sustain casualties for evacuation to fixed medical facilities for definitive care; and to ensure that personnel are medically qualified for military duty. There is a strong potential for dual use, technology transfer, and biotechnology firms/industry participation in the projects.

B. Program Change Summary (\$ in Millions)	FY 2011	FY 2012	FY 2013 Base	FY 2013 OCO	FY 2013 Total
Previous President's Budget	12.337	12.984	12.902	-	12.902
Current President's Budget	28.407	33.034	12.707	2.173	14.880
Total Adjustments	16.070	20.050	-0.195	2.173	1.978
• Congressional General Reductions	-	-			
• Congressional Directed Reductions	-	-			
• Congressional Rescissions	-	-			
• Congressional Adds	-	18.100			
• Congressional Directed Transfers	-	-			
• Reprogrammings	-	-			
• SBIR/STTR Transfer	-0.881	-			
• Program Adjustments	0.300	1.950	-0.161	2.173	2.012
• Rate/Misc Adjustments	-	-	-0.034	-	-0.034
• Congressional General Reductions	-0.149	-	-	-	-
Adjustments					
• Congressional Add Adjustments	16.800	-	-	-	-

Congressional Add Details (\$ in Millions, and Includes General Reductions)

Project: 9999: *Congressional Adds*

Congressional Add: *Military Dental Research*

Congressional Add: *Wound Care Research (transferred from Defense Health Program)*

FY 2011	FY 2012
6.367	5.100
10.347	13.000

UNCLASSIFIED

Exhibit R-2, RDT&E Budget Item Justification: PB 2013 Navy		DATE: February 2012	
APPROPRIATION/BUDGET ACTIVITY 1319: <i>Research, Development, Test & Evaluation, Navy</i> BA 5: <i>Development & Demonstration (SDD)</i>		R-1 ITEM NOMENCLATURE PE 0604771N: <i>Medical Development</i>	
Congressional Add Details (\$ in Millions, and Includes General Reductions)			
Congressional Add Subtotals for Project: 9999		FY 2011	FY 2012
		16.714	18.100
Congressional Add Totals for all Projects		16.714	18.100

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2013 Navy									DATE: February 2012		
APPROPRIATION/BUDGET ACTIVITY 1319: Research, Development, Test & Evaluation, Navy BA 5: Development & Demonstration (SDD)				R-1 ITEM NOMENCLATURE PE 0604771N: Medical Development				PROJECT 0933: Medical/Dental Equipment Dev			
COST (\$ in Millions)	FY 2011	FY 2012	FY 2013 Base	FY 2013 OCO	FY 2013 Total	FY 2014	FY 2015	FY 2016	FY 2017	Cost To Complete	Total Cost
0933: Medical/Dental Equipment Dev	11.693	14.934	12.707	2.173	14.880	9.471	9.665	10.253	10.450	Continuing	Continuing
Quantity of RDT&E Articles	0	0	0	0	0	0	0	0	0		

A. Mission Description and Budget Item Justification

The purpose of this budget item is to develop biomedical equipment and related techniques to reduce morbidity; to enhance the logistic feasibility of modern medical care for combat casualties; to sustain casualties for evacuation to fixed medical facilities for definitive care; and to ensure that personnel are medically qualified for military duty. There is a strong potential for dual use, technology transfer, and biotechnology firms/industry participation in the projects.

B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)

	FY 2011	FY 2012	FY 2013 Base	FY 2013 OCO	FY 2013 Total
Title: Medical/Dental Equipment Dev	11.693	14.934	12.707	-	12.707
Articles:	0	0	0		0
FY 2011 Accomplishments: Wound Management Program - Integrated efforts in wound closure, Hyperspectral Imaging, Heterotopic Ossification, and stem cell applications for wound repair. - Monitoring, Oxygen Ventilation and External Suction (MOVES) System - Initiated field testing and airworthiness testing for device. Continued configuration management of MOVES anesthesia module. Joint effort developed system procured by the Marine Corps. - Mobile Oxygen Ventilation and External Suction (MOVES) Anesthesia - Continued development of MOVES anesthesia module. - Intranasal Carbon Dioxide for Headache and Trigeminal Muscle Pain - Continued efforts to provide an abortive migraine therapy with minimal side effects and high efficacy for use on deployment and in Military Treatment Facilities. Led study data integrator identified to coordinate research sites. - Mitigation of Traumatic Brain Injury with Novel Pad Inserts - Continued effort to improve protection provided by helmets through a new helmet insert that will absorb shock, impact, and vibration. - Attenuated Sporozoite Malaria Vaccine for Military Personnel - Continued augmented efforts with the ongoing clinical trial effort to test, for safety and efficacy, a militarily relevant malaria vaccine regimen utilizing a promising novel vaccine candidate. - Joint Development Projects with MARCORSYSCOM Medical Acquisition - Continued Joint Development Testing and Evaluation program for medical products and equipment. Finalized development of casualty care systems for USMC Procurement.					

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2013 Navy			DATE: February 2012			
APPROPRIATION/BUDGET ACTIVITY 1319: Research, Development, Test & Evaluation, Navy BA 5: Development & Demonstration (SDD)		R-1 ITEM NOMENCLATURE PE 0604771N: Medical Development		PROJECT 0933: Medical/Dental Equipment Dev		
B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)						
		FY 2011	FY 2012	FY 2013 Base	FY 2013 OCO	FY 2013 Total
<p>- USMC Suicide Prevention Program Resiliency Study and Related Efforts - Initiated research leveraging the Marine Resiliency study, adding targeted studies of Marines that may be applicable to larger controls.</p> <p>- Transition Projects from Force Health Protection Future Capability - Initiated Development, Testing, and Evaluation program for transition products from the Office of Naval Research 6.3 Advanced Development program.</p> <p>Focused on transition of novel hemostatic agents (e.g. infusible hemostatics and field/first responder devices).</p> <p>- Treatment Response Modeling for Crew Injuries Resulting from Weapons Attack - Completed refinement of model for medical chain requirements for evacuation patient outcomes. Determined probabilistic representation of mortality function and coordinated with software developer to ensure interoperability with the Office of Naval Research.</p> <p>- Individualized Fatigue - Based Scheduling and Countermeasure System - Initiated study for development of a tool that predicted, prevented, detected, and mitigated periods of high risk associated with fatigue. Research leveraged was based upon an effort funded by the Office of Naval Research.</p> <p>OCO</p> <p>- Combined Maritime Acoustic Device and Optical (Laser) Field Test - Based on a 5th Fleet requirement, initiated an evaluation of various commercial-off-the-shelf (COTS) and government-off-the-shelf (GOTS) Non-Lethal Weapons (NLW) technology required to determine the effectiveness of a combined Acoustic and Laser device as a long-range NLW hailing and warning device. The future acquisition to deploy these types of systems in-theater will be determined by the Armed Services based on this evaluation.</p> <p>FY 2012 Plans:</p> <p>- Mobile Oxygen Ventilation and External Suction (MOVES) Anesthesia - Complete development of MOVES anesthesia module. This device is a pre-planned product improvement for FRSS deployment for MTFs, Medicine Clinics, Corpsman, and Navy or USMC Special Operations. Joint effort to result in Marine Corps procurement.</p> <p>- Attenuated Sporozoite Malaria Vaccine for Military Personnel - Complete augmented efforts with the ongoing clinical trial effort to test, for safety and efficacy, a militarily relevant malaria vaccine regimen utilizing a promising novel vaccine candidate.</p> <p>- Wound Management Program - Integrate efforts in wound closure, Hyperspectral Imaging, Heterotopic Ossification, and stem cell applications for wound repair. The system will provide improved diagnostic measures of wound healing.</p>						

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2013 Navy			DATE: February 2012			
APPROPRIATION/BUDGET ACTIVITY 1319: Research, Development, Test & Evaluation, Navy BA 5: Development & Demonstration (SDD)		R-1 ITEM NOMENCLATURE PE 0604771N: Medical Development		PROJECT 0933: Medical/Dental Equipment Dev		
B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)						
		FY 2011	FY 2012	FY 2013 Base	FY 2013 OCO	FY 2013 Total
<p>- Intranasal Carbon Dioxide for Headache and Trigeminal Muscle Pain - Complete study supporting provision of an abortive migraine therapy with minimal side effects and high efficacy for use on deployment and in Military Treatment Facilities.</p> <p>- Individualized Fatigue-Based Scheduling and Countermeasure System - Continue research supporting development of a tool that predicts, prevents, detects, and mitigates periods of high risk associated with fatigue. Coordinate with the Office of Naval Research to facilitate transition.</p> <p>- Joint Development Projects with MARCORSYSCOM Medical Acquisition - Continue Joint Development Testing and Evaluation program for medical products and equipment. Finalize development for USMC Procurement.</p> <p>- Transition Projects from Force Health Protection Future Capability - Continue Development, Testing, and Evaluation program for transition products from the Office of Naval Research 6.3 Advanced Development program. Focus will be on transition of novel hemostatic agents (e.g. infusible hemostatics and field/first responder devices).</p> <p>OCO:</p> <p>- Foreign Directed Energy System Exploitation - Exploitation of foreign directed energy devices for bioeffects.</p> <p>- Determining and Optimizing Medical Resource Requirements for Expeditionary Medical Units Engaged in OCOs - An expeditionary medical modeling and simulation tool (the Theater Medical Logistics Planning Tool (TML+)) will be configured to project and optimize medical resource requirements. Resource projection capability will be developed for Tactical Combat Casualty Care and rhesus surgery.</p> <p>- Expeditionary Medical Encounter Database (CTR EMED) - Capture expeditionary tactical and medical injury and illness data and map data to long-term casualty clinical, rehabilitative and quality of life outcome data.</p> <p>FY 2013 Base Plans:</p> <p>- Attenuated Sporozoite Malaria Vaccine for Military Personnel - Complete augmented efforts with the ongoing clinical trial effort to test, for safety and efficacy, a militarily relevant malaria vaccine regimen utilizing a promising novel vaccine candidate.</p> <p>- Individualized Fatigue-Based Scheduling and Countermeasure System - Complete research supporting development of a tool that predicts, prevents, detects, and mitigates periods of high risk associated with fatigue. Periods of high individualized performance risk will be predicted and prevented by providing individual, specific, and fatigue optimized schedules and mitigation strategies.</p> <p>- USMC Suicide Prevention Program Resiliency Study and Related Efforts - Complete research leveraging the Marine Resiliency study and the execution of targeted studies of Marines. Address aims including addition</p>						

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2013 Navy			DATE: February 2012		
APPROPRIATION/BUDGET ACTIVITY 1319: Research, Development, Test & Evaluation, Navy BA 5: Development & Demonstration (SDD)	R-1 ITEM NOMENCLATURE PE 0604771N: Medical Development	PROJECT 0933: Medical/Dental Equipment Dev			
B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)					
	FY 2011	FY 2012	FY 2013 Base	FY 2013 OCO	FY 2013 Total
of assessments to include 12-month after deployment return to determine risk for chronic PTSD and potential factors for mitigation. Effort includes assessment of postvention efforts and psychological studies. - Wound Management Program - Integrate efforts in wound closure, Hyperspectral Imaging, Heterotopic Ossification, and stem cell applications for wound repair. The system will provide improved diagnostic measures of wound healing. - Joint Development Projects with MARCORSYSCOM Medical Acquisition - Continue Joint Development Testing and Evaluation program for medical products and equipment. Finalize development for USMC Procurement. - Transition Projects from Force Health Protection Future Capability - Continue Development, Testing, and Evaluation program for transition products from the Office of Naval Research 6.3 Advanced Development program. Focus will be on transition of novel hemostatic agents (e.g. infusible hemostatics and field/first responder devices).					
Title: Tactical Logistics Planning Tool Articles: FY 2013 Base Plans: N/A FY 2013 OCO Plans: A research tool that models patient flow from the point of injury through definitive care, and an analysis tool that supports OCO operational risk assessment, field medical services planning and systems analysis. Because it can handle larger amounts of data, TML+ provides the capability to model medical treatment facilities at all levels of care and their respective functional areas, the number and type of personnel, and the type, speed, and capacity of transportation assets. The plan is to continue to develop specific modeling capabilities in TML+ to support the development of OCO medical plans that optimize clinical outcomes for combat casualties using the minimum amount of manpower, materiel, and CASEVAC/Enroute care resources.	-	-	- 0	0.481 0	0.481 0
Title: Combat Trauma Registry - Expeditionary Medical Encounter Database (CTR EMED) Articles: FY 2013 Base Plans: N/A FY 2013 OCO Plans: Tri-service database of all battle injuries, non-battle injuries, disease, and mental health encounters that occur in deployed medical treatment facilities supporting OCO. The CTR EMED tracks each casualty, develops a	-	-	- 0	0.892 0	0.892 0

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2013 Navy				DATE: February 2012	
APPROPRIATION/BUDGET ACTIVITY 1319: Research, Development, Test & Evaluation, Navy BA 5: Development & Demonstration (SDD)		R-1 ITEM NOMENCLATURE PE 0604771N: Medical Development		PROJECT 0933: Medical/Dental Equipment Dev	
B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)					
	FY 2011	FY 2012	FY 2013 Base	FY 2013 OCO	FY 2013 Total
detailed injury profile of the casualty's injuries and severities in near real-time. The tactical, operational, and casualty clinical data are forwarded to the intelligence, materiel developer and threat mitigation communities. Continue to maintain CTR EMED infrastructure necessary for supporting these OCO threat mitigation initiatives.					
Title: Validation of the Human Surrogate (HS) Prototype					
Articles:					
FY 2013 Base Plans: N/A					
FY 2013 OCO Plans: Validation of the Human Surrogate (HS) Prototype will help determine the margin of safety of microwave counter Improvised Explosive Devices (IEDs) devices and munitions. The HS model, developed by Greenwave Scientific Inc., designed to be used to make accurate measurements of the specific absorption rate (SAR) of RF energy in the human body from Counter Radio-Controlled Electronic Warfare (CREW) devices. The absorption of radiofrequency (RF) by the human body is very complex. It is well known that even uniform RF exposures lead to non-uniform absorption in almost all human exposure situations. Current methods to measure SAR in the human body are elegant and elaborate processes but they can only be carried out in the laboratory. These consist of open and closed human phantom shells filled with liquids that simulate the electrical properties of human tissue. To measure the uneven absorption of RF energy a small electric field probe is mechanically moved around inside the phantom shell during exposure.					
Continue work on the HS model and the evaluation of the accurate measurements of the specific absorption rate of radio frequent energy in the human body from Counter Radio-Controlled Electronic Warfare devices. Start developing some initial research studies looking at the long term use of the Counter Radio-Controlled Electronic Warfare devices.					
Title: Evaluation of Various Commercial and Government Off the Shelf Non-Lethal Weapons (NLW) Technology - Based on a 5th Fleet Urgent Requirement					
Articles:					
FY 2013 Base Plans: N/A					
FY 2013 OCO Plans:					

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2013 Navy			DATE: February 2012			
APPROPRIATION/BUDGET ACTIVITY 1319: Research, Development, Test & Evaluation, Navy BA 5: Development & Demonstration (SDD)		R-1 ITEM NOMENCLATURE PE 0604771N: Medical Development		PROJECT 0933: Medical/Dental Equipment Dev		
B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)						
		FY 2011	FY 2012	FY 2013 Base	FY 2013 OCO	FY 2013 Total
Based on a 5th Fleet Urgent Requirement, an evaluation of various commercial-off-the-shelf (COTS) and government-off-the-shelf (GOTS) Non-Lethal Weapons (NLW) technology is required to determine the effectiveness of a combined Acoustic and Laser device as a long range NLW hailing and warning device. The bioeffects effort will support legal, policy and treating development for these NLW devices and future acquisition to deploy these types of systems in-theatre.						
Continue the laboratory and field testing of the effectiveness of a combined Acoustic and Laser device as a long range NLW hailing and warning device. Conduct additional field testing under operational conditions.						
Accomplishments/Planned Programs Subtotals		11.693	14.934	12.707	2.173	14.880
C. Other Program Funding Summary (\$ in Millions)						
N/A						
D. Acquisition Strategy						
<p>The Medical Development Program operates with a Memorandum of Understanding with the Marine Corps Systems Command (Family of Field Medical Equipment) for co-development of products for procurement by the USMC. The acquisition strategy for these products involves direct partnership with the acquisition and procurement professionals at Marine Corps Systems Command. The program's major Product Areas in the Medical Development Program are: 1) Equipment, 2) Pharmaceuticals/ Biologics, and 3) Knowledge/Concepts. The primary Program Areas of Interest are in: 1) Expeditionary Medicine (Navy in Terrestrial, Maritime Surface, Submarine, and Aviation Operations), USMC in Expeditionary Operations. In these areas the focus is on Levels I and II in Clinical Care Medicine; and 2) Products developed for battlefield treatment of Combat Casualties and Combat Trauma, focusing on delivery of Levels III and IV of care.</p> <p>For areas 1 and 2, there are two primary acquisition strategies. The first is to test and evaluate commercially-developed medical product candidates in managed trials for ultimate Food and Drug Administration (FDA) approval. Partnerships with commercial developers ensure that products of military interest are available for procurement across the DoD, Federal Government, and commercial market. During development, DoD end users are included in the process to the extent possible. The second strategy is to drive the development process with DoD program investments. This process involves developing in-house or industrial prototypes in government-managed programs to meet military and regulatory requirements for production and fielding.</p> <p>Both strategies promote advanced preparation of procurement plans in line with the product availability. Major Medical Development programs falling in these categories are: MOVES and MOVES anesthesia module (Equipment).</p> <p>The Third Product Area (Knowledge/Concepts) is focused on the introduction of technologies, techniques, and procedures that alter medical practice and standards of care. These primarily require early involvement of the senior leadership of military medicine, in that the result of the program is modifications of concepts of operations,</p>						

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2013 Navy		DATE: February 2012
APPROPRIATION/BUDGET ACTIVITY 1319: <i>Research, Development, Test & Evaluation, Navy</i> BA 5: <i>Development & Demonstration (SDD)</i>	R-1 ITEM NOMENCLATURE PE 0604771N: <i>Medical Development</i>	PROJECT 0933: <i>Medical/Dental Equipment Dev</i>
<p>policy, and/or doctrine. These are often much smaller Medical Development Program examples include Navy/USMC Medical Planning Requirement Assessment and Crisis Action Planning Tool Transition.</p> <p>Programs such as System for Objective Decision-Making on Timing of Wound Closure involve both material and knowledge solutions.</p> <p>E. Performance Metrics</p> <p>Maintaining Scheduled Milestones/Demonstration Events for individualized project/product roadmap. Ensuring critical paths across multiple efforts are primary metrics.</p>		

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2013 Navy										DATE: February 2012				
APPROPRIATION/BUDGET ACTIVITY 1319: Research, Development, Test & Evaluation, Navy BA 5: Development & Demonstration (SDD)					R-1 ITEM NOMENCLATURE PE 0604771N: Medical Development				PROJECT 0933: Medical/Dental Equipment Dev					
Product Development (\$ in Millions)					FY 2012		FY 2013 Base		FY 2013 OCO		FY 2013 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract	
Mobile Anesthesia Delivery Module (MADM)	SS/FP	Thornhill Research, Inc. Toronto:Canada	0.874	-		-		-		-	0.000	0.874		
SLC-Cube and Weight Reduction of Moves	SS/FP	Thornhill Research, Inc. Toronto:Canada	0.450	-		-		-		-	0.000	0.450		
Malaria Vaccine	MIPR	NMRC:Silver Spring MD	0.500	3.600	Dec 2011	0.813	Dec 2012	-		0.813	0.000	4.913		
Migraine Treatment (NPDS)	C/FFP	The McConnell Group:Rockville MD	1.938	0.618	Dec 2011	-		-		-	0.000	2.556		
USMC Suicide Prevention Research	SS/FP	University of California:San Diego	2.098	2.910	Dec 2011	2.910	Dec 2012	-		2.910	0.000	7.918		
Individualized Fatigue-Based Scheduling and Countermeasure System	SS/FP	Pulsar Informatics:Philadelphia PA	0.305	1.183	Jan 2012	0.925	Dec 2012	-		0.925	Continuing	Continuing	Continuing	
Product Development	TBD	Various:Not Specified	6.409	4.673	Dec 2011	8.059	Dec 2012	-		8.059	0.000	19.141		
Medical/Dental Equipment Development (OCO)	SS/FP	Various:Not Specified	-	1.950	Jul 2012	-		2.173	Dec 2012	2.173	0.000	4.123		
Subtotal			12.574	14.934		12.707		2.173		14.880				
Remarks														
MADM is being executed as partial funding of a new contract between RDECOM Natick, MA and Thornhill Research, Inc. The total contract value is approximately \$4,100K with the project jointly funded by the Navy (\$1,000K) and the USMC for a POP through 29 JUN 2012. The first two proofs of concepts (under N00244-07-C-1531) and the breadboard (under W911QY-08-C-0116) are complete. Animal and human factors testing are ongoing. Next two phases of MADM will be focused on developing the Beta prototype and testing it on animals (base year), followed by building 10 units, verification and validation, environmental, EMC, and vibration testing, and human testing. POP for base year is 12 months which extends to 24 if the option is exercised. It is anticipated that MARCORSYSCOM will assume funding of this effort in FY12 under the existing MOA.														
The SLC program incorporates redesign and reconfiguration efforts to enhance the USMC en route care device capability set. The core program effort is supplemented by a congressional add that augments final DT&E efforts of MOVES and configuration and redesign of SLC.														
Malaria vaccine research executed as partial funding of a consortium with the National Institute of Allergy and Infectious Diseases and the Malaria Vaccine Initiative. Current year Navy Funding is \$3.6M. The product is the collaborative work between MVPP and a Gates Foundation researcher to develop a vaccine against Plasmodium falciparum. The approach is based on a prime/boost adenovaccine.														
The performers developing an intranasal treatment for migraines are the Naval Postgraduate Dental School in conjunction with a contract for the McConnell Group, which will perform a clinical trial to determine the safety and effectiveness of nasal carbon dioxide versus placebo in the treatment of moderate to severe migraine for pain and associated symptoms of nausea, photophobia and phonophobia. This clinical trial will be conducted at six military/VA treatment facilities.														
USMC Suicide Prevention Program Resiliency Study and Related Efforts - Complete research leveraging the Marine Resiliency study and the execution of targeted studies of Marines. Address aims including addition of assessments to include 12-month after deployment return to determine risk for chronic PTSD and potential factors for mitigation. Effort includes assessment of postvention efforts and psychological studies.														

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2013 Navy										DATE: February 2012				
APPROPRIATION/BUDGET ACTIVITY 1319: <i>Research, Development, Test & Evaluation, Navy</i> BA 5: <i>Development & Demonstration (SDD)</i>					R-1 ITEM NOMENCLATURE PE 0604771N: <i>Medical Development</i>					PROJECT 0933: <i>Medical/Dental Equipment Dev</i>				
Product Development (\$ in Millions)				FY 2012		FY 2013 Base		FY 2013 OCO		FY 2013 Total				
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract	
<p>Individualized Fatigue-Based Scheduling and Countermeasure System - Initial study is underway for development of a tool that predicts, prevents, detects, and mitigates periods of high risk associated with fatigue. Research leveraged is based upon an effort funded by the Office of Naval Research. Periods of high individualized performance risk will be predicted and prevented by providing individual, specific, and fatigue optimized schedules and mitigation strategies.</p> <p>Product Development incorporates numerous small efforts within major product lines to address the Navy Surgeon General's priorities. These efforts include: System for Objective Decision-making on the Timing of Wound Closure, Treatment Response Modeling, Heterotopic Ossification, Hyperspectral Imaging, Spray-dried Pooled Plasma, Psychological Autopsy Study & Intranasal Scopolamine for the Prevention of Motion Sickness in Dynamic Military Environments and Biosurveillance Information Service (BIO-SERV).</p>														
			Total Prior Years Cost	FY 2012		FY 2013 Base		FY 2013 OCO		FY 2013 Total	Cost To Complete	Total Cost	Target Value of Contract	
Project Cost Totals			12.574	14.934		12.707		2.173		14.880				
Remarks														

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2013 Navy		DATE: February 2012
APPROPRIATION/BUDGET ACTIVITY 1319: <i>Research, Development, Test & Evaluation, Navy</i> BA 5: <i>Development & Demonstration (SDD)</i>	R-1 ITEM NOMENCLATURE PE 0604771N: <i>Medical Development</i>	PROJECT 0933: <i>Medical/Dental Equipment Dev</i>

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2013 Navy		DATE: February 2012
APPROPRIATION/BUDGET ACTIVITY 1319: <i>Research, Development, Test & Evaluation, Navy</i> BA 5: <i>Development & Demonstration (SDD)</i>	R-1 ITEM NOMENCLATURE PE 0604771N: <i>Medical Development</i>	PROJECT 0933: <i>Medical/Dental Equipment Dev</i>

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2013 Navy		DATE: February 2012
APPROPRIATION/BUDGET ACTIVITY 1319: <i>Research, Development, Test & Evaluation, Navy</i> BA 5: <i>Development & Demonstration (SDD)</i>	R-1 ITEM NOMENCLATURE PE 0604771N: <i>Medical Development</i>	PROJECT 0933: <i>Medical/Dental Equipment Dev</i>

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2013 Navy		DATE: February 2012
APPROPRIATION/BUDGET ACTIVITY 1319: <i>Research, Development, Test & Evaluation, Navy</i> BA 5: <i>Development & Demonstration (SDD)</i>	R-1 ITEM NOMENCLATURE PE 0604771N: <i>Medical Development</i>	PROJECT 0933: <i>Medical/Dental Equipment Dev</i>

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2013 Navy		DATE: February 2012
APPROPRIATION/BUDGET ACTIVITY 1319: <i>Research, Development, Test & Evaluation, Navy</i> BA 5: <i>Development & Demonstration (SDD)</i>	R-1 ITEM NOMENCLATURE PE 0604771N: <i>Medical Development</i>	PROJECT 0933: <i>Medical/Dental Equipment Dev</i>

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2013 Navy		DATE: February 2012
APPROPRIATION/BUDGET ACTIVITY 1319: <i>Research, Development, Test & Evaluation, Navy</i> BA 5: <i>Development & Demonstration (SDD)</i>	R-1 ITEM NOMENCLATURE PE 0604771N: <i>Medical Development</i>	PROJECT 0933: <i>Medical/Dental Equipment Dev</i>

UNCLASSIFIED

Exhibit R-4A, RDT&E Schedule Details: PB 2013 Navy			DATE: February 2012
APPROPRIATION/BUDGET ACTIVITY 1319: <i>Research, Development, Test & Evaluation, Navy</i> BA 5: <i>Development & Demonstration (SDD)</i>	R-1 ITEM NOMENCLATURE PE 0604771N: <i>Medical Development</i>	PROJECT 0933: <i>Medical/Dental Equipment Dev</i>	

Schedule Details

Events by Sub Project	Start		End	
	Quarter	Year	Quarter	Year
<i>Proj 0933</i>				
0933 - SLC Verification and Validation Testing	1	2012	2	2012
0933 - MADM - Critical Design Review	2	2011	3	2011
0933 - MADM - Animal Studies	1	2011	4	2011
0933 - MADM - Human Studies	1	2012	4	2012
0933 - MADM - Final Report	4	2012	4	2012

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2013 Navy									DATE: February 2012		
APPROPRIATION/BUDGET ACTIVITY 1319: <i>Research, Development, Test & Evaluation, Navy</i> BA 5: <i>Development & Demonstration (SDD)</i>				R-1 ITEM NOMENCLATURE PE 0604771N: <i>Medical Development</i>				PROJECT 9999: <i>Congressional Adds</i>			
COST (\$ in Millions)	FY 2011	FY 2012	FY 2013 Base	FY 2013 OCO	FY 2013 Total	FY 2014	FY 2015	FY 2016	FY 2017	Cost To Complete	Total Cost
9999: <i>Congressional Adds</i>	16.714	18.100	-	-	-	-	-	-	-	0.000	34.814
Quantity of RDT&E Articles	0	0	0	0	0	0	0	0	0		

A. Mission Description and Budget Item Justification
Congressional Adds

B. Accomplishments/Planned Programs (\$ in Millions)	FY 2011	FY 2012
Congressional Add: Military Dental Research	6.367	5.100
FY 2011 Accomplishments: Continued the development of novel treatments for wounds based on the use of cells and factors to improve wound healing.		
FY 2012 Plans: N/A		
Congressional Add: Wound Care Research (transferred from Defense Health Program)	10.347	13.000
FY 2011 Accomplishments: The Wound Care Research Program is a comprehensive effort to develop novel diagnostics and treatments to enhance the care of the wounded warfighter. The program utilizes cutting edge molecular assays and advanced computational biology to develop a device to predict the outcome of wounds. The development of novel treatments for wounds is based on the use of cells and factors to improve wound healing.		
FY 2012 Plans: N/A		
Congressional Adds Subtotals	16.714	18.100

C. Other Program Funding Summary (\$ in Millions)
N/A

D. Acquisition Strategy
N/A

E. Performance Metrics
Not required for Congressional adds.